The speed with which IV diuretics were administered to people with acute heart failure (AHF) didn’t appear to make a difference in short- or intermediate-term mortality rates, according to a study of 2,761 Korean patients.

Todd A. Trapp will take over as CFO of Abiomed on April 9, the company announced March 30.

ABBOTT PARK, Ill., March 29, 2018 — Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of life for people living with New York Heart Association (NYHA) Class II – IV heart failure.

A new study out of Australia demonstrates rats’ heart cells not only get bigger as a result of exercise, but they can also increase in number when endurance training takes place at young ages. What’s more, the additional cells remain present into adulthood, even after the rats have become sedentary.

Two editors of JACC: Heart Failure detailed how the United States has fallen behind other countries in site-based clinical research and offered suggestions on how to reinvigorate the research culture in America.

The hearts of adults who are born prematurely don’t function as well during exercise, possibly explaining why they’re more at risk for early heart failure, according to a study published March 19 in the Journal of the American College of Cardiology.

Canagliflozin reduced the risk of death or hospitalization for heart failure by 22 percent among patients with type 2 diabetes and a high risk of cardiovascular disease, according to results of the CANVAS trial presented March 11 at the American College of Cardiology’s scientific session and published simultaneously in Circulation.

Applying natural language learning and deep neural networks to mortality risk models could help predict cardiovascular outcomes with more accuracy than modern support vector machines, researchers said at the 67th annual American College of Cardiology conference in Orlando.